新型冠状病毒肺炎重症患者相关凝血功能障碍诊疗专家共识

Expert consensus for diagnosis and treatment of coagulation dysfunction in COVID-19

2019年12月,新型冠状病毒肺炎(COVID-19)在全球暴发流行,截至2020年4月5日已出现超过126万例COVID-19患者,病死率约为5.44%。有研究显示凝血功能障碍是COVID-19重症患者死亡的重要原因之一。因此,全军重症医学专业委员会与中国研究型医院学会血栓与止血专业委员会抽取在武汉抗疫一线的专家共同制定《新型冠状病毒肺炎重症患者相关凝血功能障碍诊疗专家共识》。该共识包括COVID-19相关凝血功能障碍的概述、凝血功能评估、抗凝治疗、替代治疗、支持治疗及预防等6个部分,共18条推荐意见,以便指导临床工作。

Since December 2019,a novel type of coronavirus disease(COVID-19)in Wuhan led to an outbreak throughout the world.To date,there have been more than 1,260,000 COVID-19 patients,with a mortality rate of approximately 5.44%.Studies have shown that coagulation dysfunction is a major cause of death in patients with severe COVID-19.Therefore,the People’s Liberation Army Professional Committee of Critical Care Medicine and Chinese Thrombosis and Hemostasis Committee grouped experts from the frontline of the Wuhan epidemic to come together and develop an expert consensus on diagnosis and treatment of coagulation dysfunction associated with severe COVID-19 infection.This consensus includes an overview of COVID-19-related coagulation dysfunction,tests for coagulation,anticoagulation therapy,replacement therapy,supportive therapy and prevention.The consensus produced 18 recommendations which are being used to guide clinical work.